Comparable effect of tolvaptan in heart failure patients with preserved or reduced ejection fraction
Background: It is unclear that the difference in efficacy of tolvaptan (TLV) on the length of hospital stay for both heart failure (HF) preserved ejection fraction (EF) (HFpEF) and reduced EF (HFrEF) patients. Methods: We investigated 369 patients who were hospitalized with HF from February 2011 to...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2020-02-01
|
| Series: | Clinical and Experimental Hypertension |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/10641963.2019.1583244 |
| _version_ | 1827814256330932224 |
|---|---|
| author | Shunsuke Kiuchi Shinji Hisatake Takayuki Kabuki Takashi Oka Shintaro Dobashi Takahiro Fujii Takanori Ikeda |
| author_facet | Shunsuke Kiuchi Shinji Hisatake Takayuki Kabuki Takashi Oka Shintaro Dobashi Takahiro Fujii Takanori Ikeda |
| author_sort | Shunsuke Kiuchi |
| collection | DOAJ |
| description | Background: It is unclear that the difference in efficacy of tolvaptan (TLV) on the length of hospital stay for both heart failure (HF) preserved ejection fraction (EF) (HFpEF) and reduced EF (HFrEF) patients. Methods: We investigated 369 patients who were hospitalized with HF from February 2011 to June 2016 and initiated TLV. Patients who died in hospital, transferred hospital or clinical scenario 4 or 5 were excluded. Finally, we analyzed 108 patients with HFpEF and 96 patients with HFrEF. We evaluated the relationship between the length of hospital stay and the date of TLV initiation. Moreover, we compared the early use (within the median) and delayed use (the median or later) of TLV. Results: The date of TLV initiation was statistically associated with the length of hospital stay in both HFpEF and HFrEF (HFpEF: r = 0.625, P < 0.001, HFrEF: r = 0.618, P < 0.001). In HFpEF, the length of hospital stay in delayed use group was significantly longer than the early use group (22.2 ± 10.7 days and 38.1 ± 22.6 days, P < 0.001). The result was similar in HFrEF (22.0 ± 15.0 days and 32.1 ± 22.0 days, P = 0.008). On the other hand, there were no statistically significant differences in the length of hospital stay after initiation of TLV in both HFpEF and HFrEF. Other findings (including the severity of HF) were similar between the early use group and the delayed group in HFpEF and HFrEF. Conclusions: The time until TLV initiation after hospitalization was related to the length of hospital stay in HFpEF and HFrEF patients. |
| first_indexed | 2024-03-11T23:42:55Z |
| format | Article |
| id | doaj.art-61984d9043144e08945fd2e872872fca |
| institution | Directory Open Access Journal |
| issn | 1064-1963 1525-6006 |
| language | English |
| last_indexed | 2024-03-11T23:42:55Z |
| publishDate | 2020-02-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Clinical and Experimental Hypertension |
| spelling | doaj.art-61984d9043144e08945fd2e872872fca2023-09-19T15:19:28ZengTaylor & Francis GroupClinical and Experimental Hypertension1064-19631525-60062020-02-0142211011710.1080/10641963.2019.15832441583244Comparable effect of tolvaptan in heart failure patients with preserved or reduced ejection fractionShunsuke Kiuchi0Shinji Hisatake1Takayuki Kabuki2Takashi Oka3Shintaro Dobashi4Takahiro Fujii5Takanori Ikeda6Toho University Graduate School of MedicineToho University Graduate School of MedicineToho University Graduate School of MedicineToho University Graduate School of MedicineToho University Graduate School of MedicineToho University Graduate School of MedicineToho University Graduate School of MedicineBackground: It is unclear that the difference in efficacy of tolvaptan (TLV) on the length of hospital stay for both heart failure (HF) preserved ejection fraction (EF) (HFpEF) and reduced EF (HFrEF) patients. Methods: We investigated 369 patients who were hospitalized with HF from February 2011 to June 2016 and initiated TLV. Patients who died in hospital, transferred hospital or clinical scenario 4 or 5 were excluded. Finally, we analyzed 108 patients with HFpEF and 96 patients with HFrEF. We evaluated the relationship between the length of hospital stay and the date of TLV initiation. Moreover, we compared the early use (within the median) and delayed use (the median or later) of TLV. Results: The date of TLV initiation was statistically associated with the length of hospital stay in both HFpEF and HFrEF (HFpEF: r = 0.625, P < 0.001, HFrEF: r = 0.618, P < 0.001). In HFpEF, the length of hospital stay in delayed use group was significantly longer than the early use group (22.2 ± 10.7 days and 38.1 ± 22.6 days, P < 0.001). The result was similar in HFrEF (22.0 ± 15.0 days and 32.1 ± 22.0 days, P = 0.008). On the other hand, there were no statistically significant differences in the length of hospital stay after initiation of TLV in both HFpEF and HFrEF. Other findings (including the severity of HF) were similar between the early use group and the delayed group in HFpEF and HFrEF. Conclusions: The time until TLV initiation after hospitalization was related to the length of hospital stay in HFpEF and HFrEF patients.http://dx.doi.org/10.1080/10641963.2019.1583244tolvaptanthe length of hospital stayheart failurereduced ejection fractionpreserved ejection fraction |
| spellingShingle | Shunsuke Kiuchi Shinji Hisatake Takayuki Kabuki Takashi Oka Shintaro Dobashi Takahiro Fujii Takanori Ikeda Comparable effect of tolvaptan in heart failure patients with preserved or reduced ejection fraction Clinical and Experimental Hypertension tolvaptan the length of hospital stay heart failure reduced ejection fraction preserved ejection fraction |
| title | Comparable effect of tolvaptan in heart failure patients with preserved or reduced ejection fraction |
| title_full | Comparable effect of tolvaptan in heart failure patients with preserved or reduced ejection fraction |
| title_fullStr | Comparable effect of tolvaptan in heart failure patients with preserved or reduced ejection fraction |
| title_full_unstemmed | Comparable effect of tolvaptan in heart failure patients with preserved or reduced ejection fraction |
| title_short | Comparable effect of tolvaptan in heart failure patients with preserved or reduced ejection fraction |
| title_sort | comparable effect of tolvaptan in heart failure patients with preserved or reduced ejection fraction |
| topic | tolvaptan the length of hospital stay heart failure reduced ejection fraction preserved ejection fraction |
| url | http://dx.doi.org/10.1080/10641963.2019.1583244 |
| work_keys_str_mv | AT shunsukekiuchi comparableeffectoftolvaptaninheartfailurepatientswithpreservedorreducedejectionfraction AT shinjihisatake comparableeffectoftolvaptaninheartfailurepatientswithpreservedorreducedejectionfraction AT takayukikabuki comparableeffectoftolvaptaninheartfailurepatientswithpreservedorreducedejectionfraction AT takashioka comparableeffectoftolvaptaninheartfailurepatientswithpreservedorreducedejectionfraction AT shintarodobashi comparableeffectoftolvaptaninheartfailurepatientswithpreservedorreducedejectionfraction AT takahirofujii comparableeffectoftolvaptaninheartfailurepatientswithpreservedorreducedejectionfraction AT takanoriikeda comparableeffectoftolvaptaninheartfailurepatientswithpreservedorreducedejectionfraction |